<scp>Double‐blind</scp>, <scp>placebo‐controlled</scp> study of lurasidone monotherapy for the treatment of bipolar I depression

Abstract

Monotherapy with once daily doses of lurasidone 20-60 mg, but not 80-120 mg, significantly reduced depressive symptoms and improved functioning in patients with bipolar I depression. Results overall were consistent with previous studies, suggesting that lurasidone 20-60 mg/day is effective and safe in diverse ethnic populations, including Japanese.